2,2-dimethyl-3-(nitrooxy)propylamine nitric acid salt

• 分子结构分类: 有机化合物 - 有机氧化合物 - 有机含氧阴离子化合物
• 英文名称: 2,2-dimethyl-3-(nitrooxy)propylamine nitric acid salt
• 英文别名: 2,2-dimethyl-3-(nitrooxy)propylamine nitrate；(3-Amino-2,2-dimethylpropyl) nitrate;nitric acid
• 化学式: C₅H₁₂N₂O₃*HNO₃
• 分子量: 211.175
• InChiKey: SOXJUTCFDDZQKL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.17
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  147
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  2,2-dimethyl-3-(nitrooxy)propylamine nitric acid salt 、 吲哚美辛 在 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 以37%的产率得到N-[2,2-dimethyl-3-(nitrooxy)propyl]-2-{1-[(4-chlorophenyl)-carbonyl]-5-methoxy-2-methylindol-3-yl}acetamide
  参考文献：
  名称：

  WO2006/99416

  摘要：

  公开号：
• 作为产物：
  描述：

  3-氨基-2,2-二甲基-1-丙醇 在 硝酸 、 乙酸酐 作用下， 以 乙酸乙酯 为溶剂， 反应 0.33h， 以53%的产率得到2,2-dimethyl-3-(nitrooxy)propylamine nitric acid salt
  参考文献：
  名称：

  Structure-Based Design, Synthesis, and Biological Evaluation of Indomethacin Derivatives as Cyclooxygenase-2 Inhibiting Nitric Oxide Donors

  摘要：

  Indomethacin, a nonselective cyclooxygenase (COX) inhibitor, was modified in three distinct regions in an attempt both to increase cyclooxygenase-2 (COX-2) selectivity and to enhance drug safety by covalent attachment of an organic nitrate moiety as a nitric oxide donor. A human whole-blood COX assay shows the modifications on the 3-acetic acid part of the indomethacin yielding an amide-nitrate derivative 32 and a sulfonamide-nitrate derivative 61 conferred COX-2 selectivity. Along with their respective des-nitrate analogs, for example, 31 and 62, the nitrates 32 and 61 were effective antiinflammatory agents in the rat air-pouch model. After oral dosing, though, only 32 increased nitrate and nitrite levels in rat plasma, indicating that its nitrate tether served as a nitric oxide donor in vivo. In a rat gastric injury model, examples 31 and 32 both show a 98% reduction in gastric lesion score compared to that of indomethacin. In addition, the nitrated derivative 32 inducing 85% fewer gastric lesions when coadministered with aspirin as compared to the combination of aspirin and valdecoxib.

  DOI：

  10.1021/jm0611861

文献信息

• Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use
  申请人：Garvey David S.

  公开号：US20080287407A1

  公开（公告）日：2008-11-20

  The invention describes novel nitrosated and/or nitrosylated pyruvate compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated pyruvate compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one pyruvate compound and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one pyruvate compound, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating diseases resulting from oxidative stress, diabetes, reperfusion injury following ischemia, preservation of tissues, organs, organ parts and/or limbs.

  该发明描述了新颖的硝化和/或亚硝化丙酮酸盐及其药用可接受盐，以及包含至少一种硝化和/或亚硝化丙酮酸化合物的新型组合物，以及可选地，至少一种捐赠、转移或释放一氧化氮、刺激内源性一氧化氮合成、提高内源性内皮源性舒张因子水平或是一氧化氮合酶底物的化合物，和/或至少一种治疗剂。该发明还提供了包含至少一种丙酮酸化合物和至少一种捐赠、转移或释放一氧化氮、提高内源性内皮源性舒张因子水平、刺激内源性一氧化氮合成或是一氧化氮合酶底物和/或至少一种治疗剂的新型组合物。该发明还提供了包含至少一种丙酮酸化合物的新型试剂盒，该丙酮酸化合物可选地硝化和/或亚硝化，以及可选地至少一种一氧化氮供体和/或至少一种治疗剂。该发明还提供了治疗由氧化应激、糖尿病、缺血后再灌注损伤、组织、器官、器官部分和/或肢体保护引起的疾病的方法。
• WO2006/99416
  申请人：——

  公开号：——

  公开（公告）日：——
• Structure-Based Design, Synthesis, and Biological Evaluation of Indomethacin Derivatives as Cyclooxygenase-2 Inhibiting Nitric Oxide Donors
  作者：Shiow-Jyi Wey、Michael E. Augustyniak、Edward D. Cochran、James L. Ellis、Xinqin Fang、David S. Garvey、David R. Janero、L. Gordon Letts、Allison M. Martino、Terry L. Melim、Madhavi G. Murty、Steward K. Richardson、Joseph D. Schroeder、William M. Selig、A. Mark Trocha、Roseanne S. Wexler、Delano V. Young、Irina S. Zemtseva、Brian M. Zifcak

  DOI：10.1021/jm0611861

  日期：2007.12.13

  Indomethacin, a nonselective cyclooxygenase (COX) inhibitor, was modified in three distinct regions in an attempt both to increase cyclooxygenase-2 (COX-2) selectivity and to enhance drug safety by covalent attachment of an organic nitrate moiety as a nitric oxide donor. A human whole-blood COX assay shows the modifications on the 3-acetic acid part of the indomethacin yielding an amide-nitrate derivative 32 and a sulfonamide-nitrate derivative 61 conferred COX-2 selectivity. Along with their respective des-nitrate analogs, for example, 31 and 62, the nitrates 32 and 61 were effective antiinflammatory agents in the rat air-pouch model. After oral dosing, though, only 32 increased nitrate and nitrite levels in rat plasma, indicating that its nitrate tether served as a nitric oxide donor in vivo. In a rat gastric injury model, examples 31 and 32 both show a 98% reduction in gastric lesion score compared to that of indomethacin. In addition, the nitrated derivative 32 inducing 85% fewer gastric lesions when coadministered with aspirin as compared to the combination of aspirin and valdecoxib.